Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa

NCT04213261 is registered in ClinicalTrials.gov with Castle Creek Biosciences, LLC. as lead sponsor.

NCT NCT04213261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04213261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
Lead sponsor
Castle Creek Biosciences, LLC.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 9, 2020
Completion date
July 31, 2037
Enrollment
6 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

recessive dystrophic epidermolysis bullosa